+44 (0)20 3910 4640 info@symmetron.net
  • 🗨 We’re hiring!
Symmetron
  • Services
  • Therapeutic areas
  • The Team
  • Careers
  • Contact
Select Page

Pharmacoeconomic assessment of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare system

by Symmetron | Jan 18, 2019

Idiopathic Pulmonary Fibrosis Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System Presented at ISPOR Europe. October 29 to November 2, 2016. Vienna, Austria. Authors Triaki G, Souliotis K, Bouros...

Influence of idiopathic pulmonary fibrosis progression on healthcare resource use

by Symmetron | Jan 17, 2019

Idiopathic Pulmonary Fibrosis   Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use PharmacoEconomics Open (2018) 1-10 Authors Diamantopoulos A, Maher TM, Esser D, LeReun C Process \ Retrospective analysis of resource use data...

A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK

by Symmetron | Jan 17, 2019

Idiopathic Pulmonary Fibrosis   A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A  Process \ An...

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

by Symmetron | Jan 17, 2019

Idiopathic Pulmonary Fibrosis   The burden of illness of idiopathic pulmonary fibrosis:a comprehensive evidence review PharmacoEconomics. 2018;36:779–807 Awards Top PharmacoEconomics article of 2018! Downloads and counting Authors Diamantopoulos A, Wright E,...

Recent Comments

    Archives

    Categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Privacy Policy
    © 2019 Symmetron Ltd